Literature DB >> 17182289

Beta-lactam allergy in adults with cystic fibrosis.

Judith A Burrows1, Lisa M Nissen, Carl M J Kirkpatrick, Scott C Bell.   

Abstract

BACKGROUND: Allergic reactions to one or more beta-lactam antibiotic can pose a management problem in patients with cystic fibrosis (CF), and may limit antibiotic choice.
METHOD: The aim of this study was to assess the prevalence of allergy to anti-pseudomonal beta-lactam antibiotics in an adult CF centre and to assess variables, which may contribute to the development of allergic reactions. A questionnaire-based interview and a review of medical records were performed.
RESULTS: Of the 150 patients, 54 (36%) had allergic reactions to one or more beta-lactam antibiotics and 20 (19%) had allergic reactions to multiple beta-lactam antibiotics. The proportion of patients allergic to specific beta-lactam antibiotics varied from 10% to 26%. Rates of reactions were highest for penicillins and cephalosporins, intermediate for carbepenems and lowest for aztreonam. Of all reactions, 40% occurred within 24 h of the commencement of an individual antibiotic course. Patients with one or more beta-lactam allergic reactions had received greater cumulative exposure (p<0.0001), were older (p=0.016) and had lower lung function (p=0.037) than patients without a history of beta-lactam allergy. Cystic Fibrosis transmembrane regulator (CFTR) status, gender, peripheral blood eosinophil count and total IgE concentrations were not different in patients with allergic reactions.
CONCLUSIONS: This study demonstrates that the prevalence of allergic reactions to beta-lactam antibiotics is high in adults with CF. Increasing age; cumulative exposure and decreasing FEV(1) were associated with the development of allergy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182289     DOI: 10.1016/j.jcf.2006.11.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

1.  Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis.

Authors:  Sabah El-Ghaiesh; Manal M Monshi; Paul Whitaker; Rosalind Jenkins; Xiaoli Meng; John Farrell; Ayman Elsheikh; Daniel Peckham; Neil French; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2012-02-27       Impact factor: 4.030

2.  Challenges and safety of beta-lactam desensitization during extracorporeal membrane oxygenation.

Authors:  Dinah Foer; Kathleen Marquis; Natasha Romero; Mariana C Castells
Journal:  Ann Allergy Asthma Immunol       Date:  2019-03-13       Impact factor: 6.347

3.  Evaluation of Frequency and Characteristics of Drug Allergy in Pediatric Patients with Cystic Fibrosis.

Authors:  Zeynep Şengül Emeksiz; Pınar Metbulut; Şule Selin Akyan Soydaş; Gökçen Tuğcu; Güzin Cinel; Emine Dibek Mısırlıoğlu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2022-05-18       Impact factor: 0.885

4.  A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity.

Authors:  Henry J Legere; Ross I Palis; Tito Rodriguez Bouza; Ahmet Z Uluer; Mariana C Castells
Journal:  J Cyst Fibros       Date:  2009-09-08       Impact factor: 5.482

5.  Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis.

Authors:  Paul Whitaker; Xiaoli Meng; Sidonie N Lavergne; Sabah El-Ghaiesh; Manal Monshi; Caroline Earnshaw; Daniel Peckham; Jimmy Gooi; Steve Conway; Munir Pirmohamed; Rosalind E Jenkins; Dean J Naisbitt; B Kevin Park
Journal:  J Immunol       Date:  2011-05-23       Impact factor: 5.422

6.  Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics.

Authors:  Silvia Caimmi; Céline Sanfiorenzo; Davide Caimmi; Philippe-Jean Bousquet; Raphael Chiron; Pascal Demoly
Journal:  Clin Transl Allergy       Date:  2012-06-14       Impact factor: 5.871

Review 7.  Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.

Authors:  Yueran Li; Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Andrew Gibson; Elizabeth J Phillips
Journal:  Front Genet       Date:  2021-04-16       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.